Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Pharmaceutical Alliance Defends Section 3(d) Of Patents Act, Says Statute Not Against Incremental Innovations

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - The Indian Pharmaceutical Alliance - an influential lobbying group that represents 15 leading Indian drug makers - has stridently opposed a 2009 report published by the U.S.-India Business Council that called for certain changes in the country's Patents Act
Advertisement

Related Content

Despite Headwinds On Glivec, Novartis Gears Up To Bring Tasigna To India
Despite Headwinds On Glivec, Novartis Gears Up To Bring Tasigna To India
Novartis Suffers Setback As Indian Patent Appeals Board Strikes Down Glivec Patent
Insider Analysis From Nishith Desai Associates: Learning and Unlearning from Section 3(d) Of The Indian Patents Act (Part 1 of 2)
Insider Analysis From Nishith Desai Associates: Learning and Unlearning from Section 3(d) Of The Indian Patents Act (Part 1 of 2)
Advertisement
UsernamePublicRestriction

Register

SC074705

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel